Researchers from the U.S. National Cancer Institute recently initiated a Phase 1 clin­i­cal trial that will test whether dinaciclib in combination with Velcade and dexa­meth­a­sone is safe and effective as an anti-myeloma therapy.

The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.

Dinaciclib ^[1] (SCH727965) is currently being developed by Merck (NYSE: MRK). It is a small molecule that inhibits enzymes called cyclin-dependent kinases, which regulate the cell cycle and are often overactive in cancer cells. Dinaciclib interrupts the cell cycle by inhibiting these kinases, ultimately causing the cell to die.

Preclinical studies have shown that Velcade ^[2] (bortezomib) is more effective when cyclin-dependent kinases are inhibited, and a previous Phase 1/2 study showed that dinaciclib is safe and active as a monotherapy for relapsed/refractory myeloma (see related Beacon ^[3] news).

Therefore, this study is being conducted to determine the efficacy and safety of dinaciclib in combination with Velcade and dexamethasone ^[4] (Decadron).

For more information about the trial, see the trial description at the U.S. clinical trial registry ^[5].